SeattleGenetics®

Fact Sheet

JUNE 2018

TRANSFORMATIVE THERAPIES | TARGETING CANCER

ADCETRIS®
(brentuximab vedotin)

Quick Facts

- Antibody-drug conjugate that targets CD30, which is expressed in classical Hodgkin lymphoma as well as other types of lymphoma
- Approved in the U.S. for 5 indications for treatment of adult patients with:
  - Previously untreated Stage III or IV classical Hodgkin lymphoma (cHL)
  - cHL consolidation
  - Relapsed cHL
  - Relapsed systemic anaplastic large cell lymphoma (ALCL)
  - Relapsed primary cutaneous ALCL and CD30-expressing mycosis fungoides
- Only drug FDA-approved specifically for systemic ALCL
- Seattle Genetics has full commercialization rights in the U.S. and Canada
- Under our collaboration with Takeda Pharmaceutical Company Limited, ADCETRIS is commercially available in more than 70 countries

Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives. ADCETRIS® (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

ADCETRIS: Broad Global Development Plan

We believe that our lead program, ADCETRIS® (brentuximab vedotin), has the potential to be the foundation of care for CD30-expressing lymphomas. In March 2018, we announced the FDA granted approval for ADCETRIS in combination with chemotherapy in frontline advanced classical Hodgkin lymphoma, based on positive results from the ECHELON-1 phase 3 clinical trial. Data from that trial were published online in the *New England Journal of Medicine.*

Additionally, we are executing a broad global development plan, including our phase 3 ECHELON-2 trial, evaluating ADCETRIS plus CHP compared to standard-of-care CHOP chemotherapy in newly diagnosed patients with peripheral T-cell lymphomas, or PTCL (also referred to as mature T-cell lymphomas). Together, these approvals and trials represent significant progress toward achieving our goal to redefine the frontline standard of care options for Hodgkin lymphoma and PTCL.

Advancing Robust Pipeline with Three Programs in Late-Stage Development

We believe our multiple promising late-stage programs have the potential to help us achieve our goal of bringing additional new treatment options to patients in need.

Our pipeline includes two programs in ongoing or planned pivotal trials that utilize our proprietary ADC technology: enfortumab vedotin for metastatic urothelial cancer, in collaboration with Astellas; tisotumab vedotin for metastatic cervical cancer under our collaboration with Genmab A/S. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal clinical trial for HER2-positive metastatic breast cancer.

ADVANCING INDUSTRY-LEADING ADC Technology



Various combinations of these novel modalities are likely to be the future of treatment in oncology

Potential to Improve Patient Outcomes with Targeted Therapies

Our antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

In our ADCs, stable linkers attach a potent synthetic cell-killing (cytotoxic) agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cytotoxic agent once inside the targeted cells.

By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects.

As shown in the illustration above, other approaches to cancer treatment target pathways inside the cell or activate immune cells. Various combinations of these novel modalities are likely to be the future of treatment in oncology.

In addition to advancing our ADC research, we are applying our expertise in targets and antibodies to the area of immuno-oncology. We believe that through targeted killing of tumor cells and immunogenic cell death, ADCs could become the preferred partner for immuno-oncology agents, and are testing or plan to test brentuximab vedotin, enfortumab vedotin, tisotumab vedotin and ladiratuzumab vedotin in combinations with checkpoint inhibitors.

We also have ongoing or planned clinical trials of several novel immuno-oncology agents, including SEA-CD40 and SEA-BCMA which use our sugar-engineered antibody technology, and SGN-2FF, an oral small molecule. And, under our collaboration with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies, we are advancing ACTR-BCMA in a phase 1 trial. Additionally, we have a collaboration with Pieris Pharmaceuticals to develop multiple targeted bispecific immuno-oncology treatments.

Extending Our Opportunities through ADC Technology Collaborations

Beyond broad internal development of our antibody-drug conjugate technology, we have entered into collaborations with a number of industry-leading biotechnology and pharmaceutical companies. These licensing activities extend the reach of our technology as collaborators investigate numerous targets in many therapeutic areas.

In addition to extending the reach of our technology into additional programs, our ADC technology licensing agreements have generated approximately $400 million to date. They also provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Find more details on our ADC technology collaborator program at our website, SeattleGenetics.com.

abbvie · astellas · BAYER · Celldex therapeutics · Genentech A Member of the Roche Group · Genmab · gsk GlaxoSmithKline · Pfizer · Progenics Pharmaceuticals

Strong Oncology Pipeline

Brentuximab Vedotin

NON-HODGKIN LYMPHOMA (NHL)	ECHELON-2: Frontline CD30-expressing peripheral T-cell lymphoma (also known as MTCL)	Phase 3: Data expected in 2018
	CheckMate 436: Relapsed NHL (+ nivolumab)	Phase 1/2
HODGKIN LYMPHOMA (HL)	CheckMate 812: Relapsed HL (+ nivolumab)	Phase 3
	Frontline HL in patients 60+ (+ nivolumab)	Phase 2
	Second-line HL (+ nivolumab)	Phase 2
	CheckMate 744: Relapsed cHL (+ nivolumab)	Phase 2

Additional Late-Stage Programs

SOLID TUMORS		
Enfortumab vedotin[1]	EV-301: Urothelial cancer (post-checkpoint inhibitor)	Phase 3: Planned
	EV-201: Urothelial cancer (post-checkpoint inhibitor)	Phase 2: Pivotal
	EV-103: First-line urothelial cancer (+ checkpoint inhibitor)	Phase 1b
Tisotumab vedotin[2]	innovaTV 204: Cervical cancer	Phase 2: Pivotal
	innovaTV 207: Other solid tumors	Phase 2: Planned
BREAST CANCER		
Tucatinib	HER2CLIMB: HER2-positive breast cancer	Phase 2: Pivotal
Ladiratuzumab vedotin	I-SPY 2: HER2-negative breast cancer	Phase 2
	Triple negative breast cancer (TNBC) (+ pembrolizumab)	Phase 1b/2
	MORPHEUS: TNBC (+ atezolizumab)	Phase 1b/2
	Breast cancer	Phase 1

Early-Stage Programs

AURISTATIN ADC		
SGN-CD48A	Multiple myeloma	Phase 1
IMMUNO-ONCOLOGY		
SEA-CD40	Advanced solid tumors and lymphoma (+/- checkpoint inhibitor)	Phase 1
SGN-2FF	Advanced solid tumors	Phase 1
ACTR-BCMA[3]	Multiple myeloma	Phase 1
SEA-BCMA	Multiple myeloma	Phase 1: Planned

[1] Program being developed in collaboration with Astellas
[2] Program being developed in collaboration with Genmab
[3] Program being developed in collaboration with Unum

These are investigational uses/agents and efficacy/safety have not been established.
Visit SeattleGenetics.com for the most current pipeline status and clinical trial details.

Senior Management

Clay B. Siegall, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER

Roger D. Dansey, M.D.
CHIEF MEDICAL OFFICER

Vaughn B. Himes, Ph.D.
CHIEF TECHNICAL OFFICER

Todd E. Simpson
CHIEF FINANCIAL OFFICER

Darren Cline
EXECUTIVE VICE PRESIDENT, COMMERCIAL

Jean I. Liu, J.D.
GENERAL COUNSEL, EXECUTIVE VICE PRESIDENT, LEGAL AFFAIRS

Christopher Pawlowicz
EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES

Rachel Lenington
SENIOR VICE PRESIDENT, PORTFOLIO STRATEGY

Board of Directors

Clay B. Siegall, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS, SEATTLE GENETICS, INC.

Srinivas Akkaraju, M.D., Ph.D.
MANAGING GENERAL PARTNER, SAMSARA BIOCAPITAL

Felix J. Baker, Ph.D.
CO-MANAGING MEMBER, BAKER BROS. ADVISORS

David W. Gryska
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INCYTE CORPORATION

Marc E. Lippman, M.D.
KATHLEEN AND STANLEY GLASER PROFESSOR, CHAIRMAN OF THE DEPARTMENT OF MEDICINE, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE

John A. Orwin
FORMER CHIEF EXECUTIVE OFFICER, RELYPSA

Alpna Seth, Ph.D
CHIEF OPERATING OFFICER, VIR BIOTECHNOLOGY, INC.

Nancy A. Simonian, M.D.
CHIEF EXECUTIVE OFFICER, SYROS PHARMACEUTICALS

Daniel G. Welch
BIOTECHNOLOGY ADVISOR; FORMER CHAIRMAN AND CHIEF EXECUTIVE OFFICER, INTERMUNE

Recent Highlights

- June 2018: Announced first patient dosed in phase 2 trial of tisotumab vedotin for women with recurrent or metastatic cervical cancer
- June 2018: Presented additional analyses from phase 3 ECHELON-1 clinical trial of ADCETRIS® (brentuximab vedotin) in newly diagnosed advanced Hodgkin lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
- June 2018: Highlighted updated data from phase 1 EV-101 trial of enfortumab vedotin in oral presentation at ASCO which support rapid development program and ongoing pivotal study
- April 2018: Highlighted data at the American Association for Cancer Research (AACR) Annual Meeting from nine presentations showcasing our innovative, proprietary ADC platform technologies as well as emerging immuno-oncology pipeline
- March 2018: Received FDA Breakthrough Therapy Designation for enfortumab vedotin in locally advanced or metastatic urothelial cancer
- March 2018: Announced fifth US approval of ADCETRIS® (brentuximab vedotin) in combination with chemotherapy for adults with previously untreated Stage III or IV classical Hodgkin lymphoma
- March 2018: Announced completion of our acquisition of Cascadian Therapeutics, adding tucatinib to our pipeline
- March 2018: Announced initiation of phase 1 trial of SGN-CD48A as monotherapy in relapsed/refractory multiple myeloma

SGEN Quick Facts

NASDAQ SYMBOL
SGEN

CASH AND INVESTMENTS
$399.9 million as of March 31, 2018

COMMON STOCK OUTSTANDING
Approximately 158 million shares

FISCAL YEAR END
December 31

YEAR FOUNDED
1998

EMPLOYEES
1,225+ worldwide

GLOBAL HEADQUARTERS
Bothell, WA USA

EUROPEAN OFFICES
Zug, Switzerland

INVESTORS
Peggy Pinkston, 425.527.4160
Investors@seagen.com

MEDIA
Monique Greer, 425.527.4641
Media@seagen.com

TECHNOLOGY LICENSING
BusinessDevelopment@seagen.com

GENERAL INQUIRIES
Contact@seagen.com

FOLLOW US ON TWITTER
@SeattleGenetics

 Certain of the statements made in this fact sheet and elsewhere are forward looking. These statements are based on factors that involve risks and uncertainties, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties associated with fulfilling sales, marketing and distribution requirements; the acceptance of ADCETRIS in the marketplace; the status of reimbursement from third-party payors; risks inherent in clinical stage development and risks that our collaborators do not fulfill their obligations. For additional information on these and other factors that could affect Seattle Genetics' results, see the reports filed by the company with the SEC, which are available at www.sec.gov. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.